The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Pricing
Page 18 of 25 of this archive, newest first.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Norway declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
From the floor in Zhuhai: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
Every fortnight, every third week, seasonally: an unstudied practice
An absence of evidence is not evidence of harm. It is also not a licence.
Norway declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil caps semaglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Stepping down against stopping: two decisions treated as one
The best argument for tapering is behavioural rather than pharmacological, and it deserves to be made on its own terms.
The lowest effective dose is a real concept with almost no data behind it
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Japan caps liraglutide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Portugal declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada caps dulaglutide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Singapore caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
New Zealand caps dulaglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
From the floor in Zhuhai: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.